Actively Recruiting

Age: 18Years +
All Genders
ID07600996

A Prospective Observational Study of Cerebrospinal Fluid Mitochondrial Biomarkers Measured by Flow Cytometry in Patients With Ischemic Stroke and Alzheimer Disease Controls

Led by Capital Medical University · Updated on 2026-05-22

40

Participants Needed

1

Research Sites

13 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to study mitochondrial biomarkers in the cerebrospinal fluid of patients with ischemic stroke and Alzheimer disease controls who undergo lumbar puncture for medical reasons. The study focuses on how mitochondrial signals in cerebrospinal fluid relate to brain injury and outcomes in ischemic stroke, comparing these markers with those in Alzheimer disease patients. It is a prospective observational study conducted at Xuanwu Hospital, Capital Medical University, enrolling patients between March and May 2026. Patients diagnosed with ischemic stroke or Alzheimer disease who have a clinical indication for lumbar puncture will have their leftover cerebrospinal fluid analyzed using flow cytometry. This analysis will measure mitochondrial content with MitoTracker, mitochondrial membrane potential with JC-1, and various membrane-associated markers to identify different cell types. The study groups include an ischemic stroke cohort and an Alzheimer disease control group, with no additional interventions beyond routine care. Participants will have residual cerebrospinal fluid collected after clinical testing for detailed biomarker analysis. Researchers will assess neurological severity using admission and discharge NIHSS scores and functional outcomes with the 90-day modified Rankin Scale in stroke patients. The study will also compare mitochondrial profiles between the two patient groups. Participation involves clinical assessments and follow-up for up to 90 days after stroke onset to evaluate these outcomes.

CONDITIONS

Brief Title

A Prospective Observational Study of Cerebrospinal Fluid Mitochondrial Biomarkers Measured by Flow Cytometry in Patients With Ischemic Stroke and Alzheimer Disease Controls

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Diagnosed with ischemic stroke or Alzheimer disease based on standard clinical criteria
  • Undergoing diagnostic lumbar puncture for clinical reasons
  • Residual cerebrospinal fluid available after clinical testing
  • Able to provide written informed consent or have a legal representative provide consent
  • For ischemic stroke patients, baseline neurological assessment available and planned 90-day follow-up for functional outcome
Not Eligible

You will not qualify if you...

  • Lumbar puncture performed only for research purposes
  • Insufficient cerebrospinal fluid for analysis
  • Cerebrospinal fluid sample is grossly bloody or severely contaminated
  • Known central nervous system infection, malignant meningitis, or other inflammatory or neoplastic conditions affecting measurements
  • Unable to give informed consent
  • Missing key clinical outcome data for ischemic stroke patients
  • Any condition deemed unsuitable by the investigator for study participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - At baseline

Participants undergo diagnostic lumbar puncture as part of routine clinical evaluation, and residual cerebrospinal fluid is collected for research flow cytometry analysis to assess mitochondrial content and related markers.

1 visit (in-person) during routine clinical care

Long-term Monitoring

Duration - Up to 90 days

Participants are monitored for clinical outcomes including neurological assessments and functional status up to 90 days after stroke onset or hospital admission.

Follow-up visits as part of routine care up to 90 days

Trial Site Locations

Total: 1 location

1

Xuanwu Hospital

Beijing, None Selected, China, 100053

Actively Recruiting

Loading map...

Research Team

X

Xi Chen, MD/PhD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

18F FDG and 68Ga FAPI PET/MR Imaging of Carotid Artery Plaqu...

Carotid Artery Plaque

Actively Recruiting

1 location

Efficacy and Safety of Bevifibatide Citrate Injection in Pat...

Ischemic Stroke, Acute

Actively Recruiting

1 location

A Prospective, First in Human Pivotal Study to Evaluate the ...

Ischemic Stroke

Actively Recruiting

15 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here